IL225881B - Delayed release formulation of a non-steroidal anti-inflammatory drug - Google Patents

Delayed release formulation of a non-steroidal anti-inflammatory drug

Info

Publication number
IL225881B
IL225881B IL225881A IL22588113A IL225881B IL 225881 B IL225881 B IL 225881B IL 225881 A IL225881 A IL 225881A IL 22588113 A IL22588113 A IL 22588113A IL 225881 B IL225881 B IL 225881B
Authority
IL
Israel
Prior art keywords
sustained release
release formulation
steroidal anti
inflammatory drug
inflammatory
Prior art date
Application number
IL225881A
Other languages
English (en)
Hebrew (he)
Other versions
IL225881A0 (en
Original Assignee
Pacira Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pacira Pharmaceuticals Inc filed Critical Pacira Pharmaceuticals Inc
Publication of IL225881A0 publication Critical patent/IL225881A0/en
Publication of IL225881B publication Critical patent/IL225881B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277Preparation processes; Proliposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277Preparation processes; Proliposomes
    • A61K9/1278Post-loading, e.g. by ion or pH gradient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL225881A 2010-10-28 2013-04-22 Delayed release formulation of a non-steroidal anti-inflammatory drug IL225881B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40787210P 2010-10-28 2010-10-28
PCT/US2011/058169 WO2012058483A1 (en) 2010-10-28 2011-10-27 A sustained release formulation of a non-steroidal anti-inflammatory drug

Publications (2)

Publication Number Publication Date
IL225881A0 IL225881A0 (en) 2013-06-27
IL225881B true IL225881B (en) 2018-06-28

Family

ID=45994412

Family Applications (1)

Application Number Title Priority Date Filing Date
IL225881A IL225881B (en) 2010-10-28 2013-04-22 Delayed release formulation of a non-steroidal anti-inflammatory drug

Country Status (7)

Country Link
US (6) US10610486B2 (https=)
EP (1) EP2632553B1 (https=)
JP (3) JP6194248B2 (https=)
CN (1) CN103260702B (https=)
ES (1) ES2770575T3 (https=)
IL (1) IL225881B (https=)
WO (1) WO2012058483A1 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6194248B2 (ja) 2010-10-28 2017-09-06 パシラ ファーマシューティカルズ インコーポレーテッド 非ステロイド性抗炎症薬の徐放性処方物
BR112013016365A2 (pt) * 2010-12-27 2018-06-26 Terumo Corp composição de lipossoma e processo para produção do mesmo
EP2680820B1 (en) * 2011-03-01 2022-11-02 2-BBB Medicines B.V. Advanced active liposomal loading of poorly water-soluble substances
EP2846773A4 (en) 2012-05-10 2015-12-30 Painreform Ltd DEPOT FORMULATIONS OF A LOCAL ANESTHETICS AND METHOD FOR THE MANUFACTURE THEREOF
SI2854769T1 (sl) 2012-07-05 2023-09-29 Taiwan Liposome Company, Ltd. Postopki za zdravljenje artritisa
HK1231397A1 (zh) * 2014-01-14 2017-12-22 The Johns Hopkins University 包封修饰的环糊精复合物的脂质体组合物及其应用
EP3142656B1 (en) * 2015-01-21 2018-10-17 Pacira Pharmaceuticals, Inc. Multivesicular liposome formulations of tranexamic acid
GB201505527D0 (en) 2015-03-31 2015-05-13 Jmedtech Pte Ltd Composition
US10213284B2 (en) 2015-06-30 2019-02-26 Tela Bio, Inc. Corner-lock stitch patterns
WO2017015421A1 (en) 2015-07-21 2017-01-26 Tela Bio, Inc. Compliance control stitching in substrate materials
US10751306B2 (en) 2015-11-06 2020-08-25 The Johns Hopkins University Methods of treating liver fibrosis by administering 3-bromopyruvate
EP3448308B1 (en) 2016-04-26 2024-08-14 Tela Bio, Inc. Hernia repair grafts having anti-adhesion barriers
CN106491533B (zh) * 2016-11-11 2019-08-20 江苏九旭药业有限公司 一种稳定的氟比洛芬酯组合物及制备方法
EP3541815A4 (en) * 2016-11-18 2020-07-15 Pacira Pharmaceuticals, Inc. ZINC MELXICAM COMPLEX MICROPARTICLE MULTIVESICULAR LIPOSOME FORMULATIONS AND METHODS OF MAKING THE SAME
KR102069680B1 (ko) * 2017-03-02 2020-01-23 단디바이오사이언스 주식회사 면역억제인자 제어물질을 포함하는 다중도메인캡슐, 이의 제조방법, 및 이를 포함하는 면역조절 조성물
WO2019071245A1 (en) 2017-10-06 2019-04-11 Foundry Therapeutics, Inc. IMPLANTABLE DEPOSITS FOR REGULATED RELEASE OF ANALGESICS TO TREAT POSTHOPERATIVE PAIN ASSOCIATED WITH ORTHOPEDIC SURGERY, AND RELATED DEVICES, SYSTEMS, AND METHODS
CN116650732A (zh) 2018-01-08 2023-08-29 铸造疗法股份有限公司 经由治疗剂的控制递送用于治疗腔内癌症的装置、系统和方法
EP3761963B1 (en) 2018-03-09 2025-01-22 Tela Bio, Inc. Surgical repair graft
US12458589B2 (en) 2018-05-12 2025-11-04 Foundry Therapeutics, Inc. Implantable polymer depots for the controlled release of therapeutic agents
WO2020047013A1 (en) 2018-08-28 2020-03-05 Foundry Therapeutics, Inc. Polymer implants
AU2019339401B9 (en) * 2018-09-14 2022-11-03 Pharmosa Biopharm Inc. Pharmaceutical composition for controlled release of weak acid drugs and uses thereof
JP7229012B2 (ja) * 2018-12-25 2023-02-27 小林製薬株式会社 内服用医薬組成物
US11446130B2 (en) 2019-03-08 2022-09-20 Tela Bio, Inc. Textured medical textiles
CN114732786A (zh) * 2021-01-07 2022-07-12 广州曼翔医药有限公司 一种注射用氯诺昔康脂质体
US12151024B2 (en) 2021-01-22 2024-11-26 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11033495B1 (en) 2021-01-22 2021-06-15 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11278494B1 (en) 2021-01-22 2022-03-22 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11357727B1 (en) 2021-01-22 2022-06-14 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
CN113509440B (zh) * 2021-03-26 2022-08-30 中国药科大学 一种高包封率酮咯酸多囊脂质体制备及提高其稳定性方法
CN113616597B (zh) * 2021-08-02 2026-04-07 上海交通大学 一种美洛昔康的注射剂及其制备方法和用途
EP4415713A4 (en) 2021-10-14 2025-08-06 Pacira Pharmaceuticals Inc MULTIVESICULAR LIPOSOME FORMULATIONS OF BUPIVACAINE AND THEIR USES
CN116077435B (zh) * 2023-04-07 2023-06-02 山东恒邦中科生物工程有限公司 一种兽用高浓度美洛昔康注射剂的制备方法
US12156940B1 (en) 2024-05-20 2024-12-03 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US12280149B1 (en) 2024-05-20 2025-04-22 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US12251472B1 (en) 2024-05-20 2025-03-18 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3547119A (en) 1967-12-08 1970-12-15 Baxter Laboratories Inc Catheter assembly
US4311137A (en) 1980-04-30 1982-01-19 Sherwood Medical Industries Inc. Infusion device
US4612370A (en) 1982-04-02 1986-09-16 The Regents Of The University Of California Lipid-saccharide reaction products
US4531937A (en) 1983-01-24 1985-07-30 Pacesetter Systems, Inc. Introducer catheter apparatus and method of use
US4565696A (en) 1983-08-03 1986-01-21 The Regents Of The University Of California Production of immunogens by antigen conjugation to liposomes
US4897355A (en) * 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5230899A (en) 1985-08-07 1993-07-27 Smithkline Beecham Corporation Methods and compositions for making liposomes
US4755173A (en) 1986-02-25 1988-07-05 Pacesetter Infusion, Ltd. Soft cannula subcutaneous injection set
GB8607717D0 (en) 1986-03-27 1986-04-30 Unilever Plc Hydratable powders
US6759057B1 (en) * 1986-06-12 2004-07-06 The Liposome Company, Inc. Methods and compositions using liposome-encapsulated non-steroidal anti-inflammatory drugs
WO1987007506A1 (en) 1986-06-12 1987-12-17 The Liposome Company, Inc. Methods and compositions using liposome-encapsulated non-steroidal anti-inflammatory drugs
JPH01501622A (ja) * 1986-06-12 1989-06-08 ザ リポソーム カンパニー,インコーポレイテッド リポソームにカプセル包囲された非ステロイド性抗炎症薬を用いる方法および組成物
US5204112A (en) 1986-06-16 1993-04-20 The Liposome Company, Inc. Induction of asymmetry in vesicles
US4877619A (en) 1986-08-25 1989-10-31 Vestar, Inc. Liposomal vesicles for intraperitoneal administration of therapeutic agents
US5723147A (en) 1987-02-23 1998-03-03 Depotech Corporation Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride
GB8704171D0 (en) 1987-02-23 1987-04-01 Clayton Found Res Multivesicular liposomes
US5576017A (en) 1988-05-30 1996-11-19 Depotech Corporation Heterovesicular liposomes
AU664359B2 (en) * 1990-12-03 1995-11-16 Nexstar Pharmaceuticals, Inc. Prevention of synovial adhesions
US5230800A (en) 1992-02-20 1993-07-27 Minnesota Mining And Manufacturing Company Scrim inserted electrostatic fibrous filter web
US5545143A (en) 1993-01-21 1996-08-13 T. S. I. Medical Device for subcutaneous medication delivery
PT695169E (pt) 1993-04-22 2003-04-30 Skyepharma Inc Lipossomas multivesiculares de ciclodextrina encapsulando compostos farmacologicos e metodos para a sua utilizacao
AU686277B2 (en) * 1993-11-16 1998-02-05 Pacira Pharmaceuticals, Inc. Vesicles with controlled release of actives
US5766627A (en) 1993-11-16 1998-06-16 Depotech Multivescular liposomes with controlled release of encapsulated biologically active substances
US5993850A (en) 1994-09-13 1999-11-30 Skyepharma Inc. Preparation of multivesicular liposomes for controlled release of encapsulated biologically active substances
US6193963B1 (en) 1996-10-17 2001-02-27 The Regents Of The University Of California Method of treating tumor-bearing patients with human plasma hyaluronidase
US5891467A (en) 1997-01-31 1999-04-06 Depotech Corporation Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes
FR2763958A1 (fr) 1997-05-29 1998-12-04 Transgene Sa Produit de combinaison associant un acide nucleique a une substance desorganisant la matrice extracellulaire pour la therapie genique
US6306432B1 (en) * 1997-09-08 2001-10-23 Chiron Corporation High and low load formulations of IGF-I in multivesicular liposomes
US6106858A (en) 1997-09-08 2000-08-22 Skyepharma, Inc. Modulation of drug loading in multivescular liposomes
CA2304096C (en) 1997-09-18 2003-09-09 Pacira Pharmaceuticals, Inc. Sustained-release liposomal anesthetic compositions
WO1999022601A1 (en) 1997-11-05 1999-05-14 Biozone Laboratories, Inc. Enhanced infant formula containing liposome encapsulated nutrients and agents
AU752802C (en) 1997-11-14 2006-04-13 Pacira Pharmaceuticals, Inc. Production of multivesicular liposomes
IL140892A0 (en) 1998-08-12 2002-02-10 Yissum Res Dev Co Liposomal bupivacaine compositions prepared using an ammonium sulfate gradient
US20020114829A1 (en) 1998-12-18 2002-08-22 Hayat Onyuksel Materials and methods for making improved liposome compositions
US20020009466A1 (en) 1999-08-31 2002-01-24 David J. Brayden Oral vaccine compositions
US20020035107A1 (en) 2000-06-20 2002-03-21 Stefan Henke Highly concentrated stable meloxicam solutions
EP1372573B1 (en) 2001-03-21 2009-10-07 Madash LLC Thermally reversible water in oil in water emulsions
US20020169102A1 (en) 2001-04-03 2002-11-14 Frey William H. Intranasal delivery of agents for regulating development of implanted cells in the CNS
US6709663B2 (en) * 2001-08-31 2004-03-23 Healthpoint, Ltd. Multivesicular emulsion drug delivery systems
US8043602B2 (en) 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
US20030235610A1 (en) * 2002-06-21 2003-12-25 Piedmont Pharmaceuticals, Llc Liposomes containing biologically active compounds
US7485670B2 (en) 2002-08-02 2009-02-03 Cambridge Polymer Group, Inc. Systems and methods for controlling and forming polymer gels
US20040105881A1 (en) * 2002-10-11 2004-06-03 Gregor Cevc Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
US20040224010A1 (en) * 2002-11-15 2004-11-11 Optime Therapeutics, Inc. Ophthalmic liposome compositions and uses thereof
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
NZ542873A (en) 2003-03-05 2008-07-31 Halozyme Inc Soluble, neutral-active hyaluronidase activity glycoprotein (sHASEGP) that is produced with high yield in a mammalian expression system by introducing nucleic acids that lack a narrow region encoding amino acids in the carboxy terminus of the human PH20 cDNA
US20070009583A1 (en) 2003-10-10 2007-01-11 Qvist Michael H Dressing
US20050268425A1 (en) 2004-04-20 2005-12-08 Clemons William E Sr Surface cleaner
US8129359B2 (en) 2004-06-04 2012-03-06 Ethicon, Inc. Composition and method for treating post-surgical pain
ES2490595T3 (es) 2005-02-17 2014-09-04 Abbott Laboratories Administración transmucosal de composiciones de fármacos para tratar y prevenir trastornos en animales
WO2006096571A2 (en) 2005-03-04 2006-09-14 President And Fellows Of Harvard College Method and apparatus for forming multiple emulsions
EP1904183B1 (en) 2005-07-05 2014-10-15 Purdue Research Foundation Pharmaceutical composition for the treatment of osteoarthritis
AU2006307460A1 (en) * 2005-10-26 2007-05-03 New York University A method for preparing liposomes and uses thereof
US8097646B2 (en) 2005-11-07 2012-01-17 Alpharx, Inc. Ophthalmic preparation containing menthyl ester of indomethacin
CN101410123A (zh) * 2006-03-28 2009-04-15 杰佛林制药公司 低剂量的双氯芬酸和β-环糊精的制剂
WO2007134819A1 (en) 2006-05-18 2007-11-29 Medigene Ag Cationic liposomal preparations for the treatment of rheumatoid arthritis
WO2008030818A2 (en) 2006-09-05 2008-03-13 Mebiopharm Co., Ltd. Novel liposome compositions
US20080075807A1 (en) 2006-09-22 2008-03-27 Baldwin Cheryl J Methods Of Fortifying Foods With Vitamin D And Food Products Thereof
ES2353900T3 (es) * 2006-09-28 2011-03-08 Losan Pharma Gmbh Formulación de solubilización rápida de fármacos antiinflamatorios no esteroideos.
ES2559521T3 (es) 2006-10-16 2016-02-12 Thesan Pharmaceuticals, Inc. Pirazolil tienopiridinas terapéuticas
US8268347B1 (en) * 2006-10-24 2012-09-18 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
US8071127B2 (en) * 2006-10-24 2011-12-06 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
WO2008073317A2 (en) 2006-12-08 2008-06-19 Musc Foundation For Research Development Cytarabine for treatment of glioma
EP1932516A1 (en) 2006-12-11 2008-06-18 Universiteit Utrecht Holding B.V. Anti-inflammatory compounds containing compositions for treatment of cancer
US20090311237A1 (en) 2008-04-14 2009-12-17 Frost Gregory I Combination therapy using a soluble hyaluronidase and a bisphosphonate
US8062663B2 (en) 2008-05-23 2011-11-22 National Health Research Instittues Methods and compostions for enhancing transdermal drug delivery
WO2009147684A2 (en) 2008-06-06 2009-12-10 Quark Pharmaceuticals, Inc. Compositions and methods for treatment of ear disorders
TW201004658A (en) * 2008-07-31 2010-02-01 Enzon Pharmaceuticals Inc Nanoparticle compositions for nucleic acids delivery system
US8361935B2 (en) 2008-08-29 2013-01-29 Schlumberger Technology Corporation Metal free crosslinking of galactomannan
EP2342340A1 (en) 2008-09-22 2011-07-13 Rxi Pharmaceuticals Corporation Rna interference in skin indications
CN101744764A (zh) * 2008-12-09 2010-06-23 上海医药工业研究院 一种空白和含盐酸拓扑替康的多囊脂质体及其制备方法
CN102264370A (zh) 2008-12-23 2011-11-30 艾米拉制药公司 投与眼的flap抑制剂的局部调配物
WO2010113983A1 (ja) * 2009-03-30 2010-10-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 リポソーム組成物の製造方法
US20110250264A1 (en) 2010-04-09 2011-10-13 Pacira Pharmaceuticals, Inc. Method for formulating large diameter synthetic membrane vesicles
JP6194248B2 (ja) 2010-10-28 2017-09-06 パシラ ファーマシューティカルズ インコーポレーテッド 非ステロイド性抗炎症薬の徐放性処方物
SI2854769T1 (sl) * 2012-07-05 2023-09-29 Taiwan Liposome Company, Ltd. Postopki za zdravljenje artritisa
CA2843943A1 (en) 2014-02-20 2014-05-28 Pankaj Modi Oral formulations of chemotherapeutic agents
US10137325B2 (en) * 2014-03-24 2018-11-27 Shantha Sarangapani System and method for deactivation and disposal of a pharmaceutical dosage form
JP6584146B2 (ja) 2015-05-27 2019-10-02 キヤノン株式会社 プリント装置

Also Published As

Publication number Publication date
US10675245B2 (en) 2020-06-09
US20130189348A1 (en) 2013-07-25
US10729651B2 (en) 2020-08-04
JP2018065877A (ja) 2018-04-26
US10610486B2 (en) 2020-04-07
EP2632553B1 (en) 2020-01-01
JP2016040332A (ja) 2016-03-24
US20130183374A1 (en) 2013-07-18
US20130209548A1 (en) 2013-08-15
EP2632553A1 (en) 2013-09-04
US20130189350A1 (en) 2013-07-25
IL225881A0 (en) 2013-06-27
JP6194248B2 (ja) 2017-09-06
ES2770575T3 (es) 2020-07-02
US20130209547A1 (en) 2013-08-15
JP2013540824A (ja) 2013-11-07
CN103260702A (zh) 2013-08-21
US9974744B2 (en) 2018-05-22
CN103260702B (zh) 2018-07-27
WO2012058483A1 (en) 2012-05-03
US10617642B2 (en) 2020-04-14
JP6305973B2 (ja) 2018-04-04
EP2632553A4 (en) 2016-07-20
US10123974B2 (en) 2018-11-13
US20120114740A1 (en) 2012-05-10

Similar Documents

Publication Publication Date Title
IL225881B (en) Delayed release formulation of a non-steroidal anti-inflammatory drug
PL2524692T3 (pl) Przeciwzapalny, przeciwbólowy plaster adhezyjny do zewnętrznego stosowania
ZA201306237B (en) Solid forms of a pharmaceutically active substance
ME03364B (me) Formulacija lijeka sa odloženim otpuštanjem
IL222919A0 (en) Alcohol - resistant oral pharmaceutical form
BR112013013571A2 (pt) comprimido para a desintegração oral
EP2654638A4 (en) COMPOSITION FOR TRANSDERMAL ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY DRUG
EP2560484A4 (en) PHARMACEUTICAL COMPOSITION FROM NANOPARTICLES
LT2648696T (lt) Nauja racekadotrilio skyrimo forma
IT1401142B1 (it) Procedimento per la preparazione di compresse a rilascio controllato comprendenti melatonina
ZA201209038B (en) Adhesive slow-release formulations for the local administration of curcumin
PL2787983T3 (pl) Plaster zawierający niesteroidowy lek przeciwzapalny
AP2014007760A0 (en) Stabilized pharmaceutical formulations of a potentHCV inhibitor
GB201001203D0 (en) Use of pharmaceutically active compounds
SMT202100289T1 (it) Pasta comprendente il farmaco antinfiammatorio non steroideo meloxicam
BR112013014963A2 (pt) comprimido farmacêutico de liberação controlada para administração oral
PL390788A1 (pl) Betulina do zastosowania jako lek na choroby wątroby
GB201009603D0 (en) Anti-inflammatory agent
FI20100072A0 (fi) Uudenlainen formulaatio
GB201001335D0 (en) Drug release formulations
GB201006090D0 (en) New target for anti-inflammatory drugs
HU1000429D0 (en) Basic salts of a pharmaceutical active ingredient
GB201111387D0 (en) Prodrugs of pharmacologically active phenolic drug metabolites and uses thereof
HK1190074A (en) Sustained release paracetamol formulations
GB201016615D0 (en) Drug release composition

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed